National Cancer Institute (NCI): Pancreatic Neoplasms trials

The registry lists 110 Pancreatic Neoplasms studies with National Cancer Institute (NCI) as lead sponsor. 14 are open to participants now and 37 have results posted.

Phase 1 56Phase 2 61Phase 3 1No phase 7(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal AdenocarcinomaRecruitingNCT07619521Phase 1/2
• The Vanguard Study: Testing a New Way to Screen for CancerRecruitingNCT06995898Not applicable
• Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including MesotheliomaRecruitingNCT06885697Phase 1
• Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine TumorsRecruitingNCT05687123Phase 1
• Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor MicroenvironmentEnrolling by invitationNCT05600933
• Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 GeneRecruitingNCT05372614Phase 1
• Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid TumorsRecruitingNCT05053971Phase 1/2
• Metarrestin (ML-246) in Subjects With Metastatic Solid TumorsRecruitingNCT04222413Phase 1
• Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine TumorsRecruitingNCT04074135Phase 2
• Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 PatientsRecruitingNCT03190941Phase 1/2
• Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing CancersRecruitingNCT02830724Phase 1/2
• Tissue Procurement and Natural History Study of Patients With Malignant MesotheliomaRecruitingNCT01950572
• Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of CancerRecruitingNCT01915225
• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic CancerRecruitingNCT01174121Phase 2
• Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid TumorsActive, not recruitingNCT04616534Phase 1Results posted
• Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic CancerActive, not recruitingNCT04514497Phase 1Results posted
• Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas CancerTerminatedNCT04327986Phase 1/2Results posted
• Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal CancersCompletedNCT03801915Phase 2Results posted
• Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic CancersTerminatedNCT03785210Phase 2Results posted
• Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 PatientsTerminatedNCT03745326Phase 1/2Results posted
• M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the PancreasTerminatedNCT03451773Phase 1/2Results posted
• Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R MutationsCompletedNCT03040986Phase 2Results posted
• FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic CancerCompletedNCT02890355Phase 2Results posted
• Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid TumorsCompletedNCT02810418Phase 1/2Results posted
• Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic CancerCompletedNCT02311361Phase 1/2Results posted
• Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by SurgeryCompletedNCT02194829Phase 1/2Results posted
• Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With ChemotherapyCompletedNCT01658943Phase 2Results posted
• Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerActive, not recruitingNCT01585805Phase 2Results posted
• CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic CancerTerminatedNCT01583686Phase 1/2Results posted
• Predictors of Tumor Response and of Radiation Therapy Side Effects in Patients With Gastrointestinal CancersTerminatedNCT01445327Results posted
• SS1P and Pentostatin Plus Cyclophosphamide for MesotheliomaCompletedNCT01362790Phase 1/2Results posted
• Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP TrialCompletedNCT01294358Phase 1Results posted
• Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic CancerCompletedNCT01280058Phase 2Results posted
• Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas CancerCompletedNCT01232829Phase 2Results posted
• Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerCompletedNCT01222689Phase 2Results posted
• Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic CancerCompletedNCT01195415Phase 2Results posted
• Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic CancerCompletedNCT01064622Phase 2Results posted
• Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell CancerCompletedNCT01010126Phase 2Results posted
• Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic CancerCompletedNCT00735917Phase 2Results posted
• S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By SurgeryCompletedNCT00617708Phase 1/2Results posted
• Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic CancerCompletedNCT00577889Phase 2Results posted
• Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by SurgeryTerminatedNCT00482625Phase 2Results posted
• Dasatinib in Treating Patients With Metastatic Pancreatic CancerCompletedNCT00474812Phase 2Results posted
• Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine CancerCompletedNCT00454363Phase 2Results posted
• Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic CancerTerminatedNCT00416793Phase 2Results posted
• Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer PatientsCompletedNCT00383760Phase 2Results posted
• Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic CancerCompletedNCT00331682Phase 2Results posted
• Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By SurgeryCompletedNCT00305877Phase 2Results posted
• Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic CancerCompletedNCT00114244Phase 2Results posted
• Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic CancerCompletedNCT00091026Phase 2Results posted
• Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic CancerCompletedNCT00031694Phase 2Results posted
• A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal MalignanciesWithdrawnNCT06690281Phase 2
• CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic CancerSuspendedNCT05685602Phase 1
• Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment TrialActive, not recruitingNCT05554367Phase 2
• Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic CancerActive, not recruitingNCT05411094Phase 1
• Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair VariationsActive, not recruitingNCT04550494Phase 2
• Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA MutationsActive, not recruitingNCT04548752Phase 2
• Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic CancerSuspendedNCT04172532Phase 1/2
• Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and LymphomasWithdrawnNCT03925428Phase 1
• Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic CancerActive, not recruitingNCT03816358Phase 1
• M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryActive, not recruitingNCT02595931Phase 1
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
• Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by SurgeryCompletedNCT01783171Phase 1
• Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by SurgeryActive, not recruitingNCT01660971Phase 1
• Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver DysfunctionCompletedNCT01638533Phase 1
• TKM 080301 for Primary or Secondary Liver CancerCompletedNCT01437007Phase 1
• CT-011 and p53 Genetic Vaccine for Advanced Solid TumorsWithdrawnNCT01386502Phase 1
• Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid TumorsCompletedNCT01352962Phase 1
• Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung CancerTerminatedNCT01282333Phase 1
• Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid TumorsTerminatedNCT01233505Phase 1
• Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine CarcinomaCompletedNCT01204476Phase 1
• RO4929097 Before Surgery in Treating Patients With Pancreatic CancerTerminatedNCT01192763Phase 1
• Gamma-Secretase Inhibitor RO4929097 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid TumorsCompletedNCT01145456Phase 1
• Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid TumorsCompletedNCT01131234Phase 1
• Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous TherapyCompletedNCT00892736Phase 1
• GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by SurgeryActive, not recruitingNCT00878163Phase 1
• Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid TumorsCompletedNCT00462553Phase 1
• Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With GemcitabineCompletedNCT00397787Phase 2
• Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerCompletedNCT00397384Phase 1
• 3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By SurgeryCompletedNCT00288093Phase 1
• Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic CancerWithdrawnNCT00253526Phase 2
• Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By SurgeryCompletedNCT00114179Phase 2
• Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung CancerCompletedNCT00101348Phase 1/2
• Surgery for Pancreatic Tumors and Collection of Tumor Tissue for StudyTerminatedNCT00100321
• Radiotherapy Combined With Oxaliplatin and Fluorouracil Followed By Gemcitabine in Treating Patients With Locally Advanced, Unresectable Pancreatic CancerCompletedNCT00096070Phase 2
• Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerCompletedNCT00095966Phase 2
• Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerCompletedNCT00088894Phase 3
• EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung CancerTerminatedNCT00087191Not applicable
• Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the PancreasCompletedNCT00085371Phase 2
• CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerCompletedNCT00075647Phase 2
• Immunotoxin Therapy in Treating Patients With Advanced Solid TumorsCompletedNCT00066651Phase 1
• Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic CancerCompletedNCT00063947Phase 1
• Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic CancerCompletedNCT00052689Phase 2
• Flavopiridol Plus Radiation Therapy Followed By Gemcitabine Hydrochloride in Treating Patients With Locally Advanced, Unresectable Pancreatic CancerCompletedNCT00047307Phase 1
• UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic CancerCompletedNCT00039403Phase 1
• 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)CompletedNCT00031681Phase 1
• Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionCompletedNCT00030498Phase 1
• Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic CancerCompletedNCT00028834Phase 2
• Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic CancerCompletedNCT00028496Phase 1
• Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic CancerCompletedNCT00026104Phase 2